Erica Rappold

1.5k total citations
28 papers, 1.1k citations indexed

About

Erica Rappold is a scholar working on Oncology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Erica Rappold has authored 28 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Genetics and 11 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Erica Rappold's work include Chronic Lymphocytic Leukemia Research (14 papers), HER2/EGFR in Cancer Research (11 papers) and Advanced Breast Cancer Therapies (8 papers). Erica Rappold is often cited by papers focused on Chronic Lymphocytic Leukemia Research (14 papers), HER2/EGFR in Cancer Research (11 papers) and Advanced Breast Cancer Therapies (8 papers). Erica Rappold collaborates with scholars based in United States, United Kingdom and France. Erica Rappold's co-authors include Julie Byrne, María Koehler, A. Preston, Michael S. Ewer, Edith A. Perez, Paul E. Goss, Julien Mazières, George R. Blumenschein, Frank Wu and Myung‐Ju Ahn and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Erica Rappold

27 papers receiving 1.1k citations

Peers

Countries citing papers authored by Erica Rappold

Since Specialization

Citations

This map shows the geographic impact of Erica Rappold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erica Rappold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erica Rappold more than expected).

Fields of papers citing papers by Erica Rappold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erica Rappold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erica Rappold. The network helps show where Erica Rappold may publish in the future.

Co-authorship network of co-authors of Erica Rappold

This figure shows the co-authorship network connecting the top 25 collaborators of Erica Rappold. A scholar is included among the top collaborators of Erica Rappold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erica Rappold. Erica Rappold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open‐label study 2024 ·American Journal of Hematology ·Wilma Barcellini, Fabrizio Pane, Andrea Patriarca, (unknown), Louis Terriou, Maria T. DeSancho, Wahid T. Hanna, Lance Leopold, Erica Rappold, (unknown), (unknown), Ulrich Jäger	2
2	Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL‑112) 2024 ·Leukemia & lymphoma ·Juan‐Manuel Sancho, Pau Abrisqueta, Abhijeet Kumar, Raúl Córdoba, Monica Tani, Peter Langmuir, Erica Rappold, (unknown), Armando López‐Guillermo	1
3	A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204) 2023 ·Blood Advances ·Tycel Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Zinzani, Catherine Thiéblemont, Wojciech Jurczak, (unknown), Erica Rappold, (unknown), Ping Jiang, Peter Johnson	6
4	Parsaclisib in Japanese patients with relapsed or refractory B‐cell lymphoma (CITADEL‐111): A phase Ib study 2022 ·Cancer Science ·Noriko Fukuhara, Youko Suehiro, Harumi Kato, Shigeru Kusumoto, (unknown), Erica Rappold, (unknown), Jia V. Li, Aidan G. Gilmartin, Koji Izutsu	7
5	Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204) 2021 ·Blood ·Tycel Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Zinzani, Catherine Thiéblemont, Wojciech Jurczak, (unknown), Erica Rappold, Wanying Zhao, Peter Johnson	3
6	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) 2020 ·Blood ·Tycel Phillips, Paolo Corradini, Ronit Gurion, Caterina Patti, Monica Tani, Abraham Avigdor, Wojciech Jurczak, Amitkumar Mehta, Pier Luigi Zinzani, Izidore S. Lossos, Catherine Thiéblemont, (unknown), Erica Rappold, Wanying Zhao, Peter Johnson	16
7	Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy 2016 ·European Journal of Cancer ·Kathrin Strasser‐Weippl, Nora Horick, Ian E. Smith, Joyce O’Shaughnessy, Bent Ejlertsen, Frances Boyle, Aman U. Buzdar, P. Fumoleau, William J. Gradishar, Miguel Martín, Beverly Moy, Martine Piccart, Kathleen I. Pritchard, Deborah Lindquist, Erica Rappold, Dianne M. Finkelstein, Paul E. Goss	4
8	Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy 2015 ·Breast Cancer Research ·Kathrin Strasser‐Weippl, Nora Horick, Ian E. Smith, Joyce O’Shaughnessy, Bent Ejlertsen, Frances Boyle, Aman U. Buzdar, P. Fumoleau, William J. Gradishar, Miguel Martín, Beverly Moy, Martine Piccart, Kathleen I. Pritchard, Deborah Lindquist, Erica Rappold, Dianne M. Finkelstein, Paul E. Goss	26
9	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) 2015 ·Annals of Oncology ·George R. Blumenschein, Egbert F. Smit, David Planchard, Dongwook Kim, J. Cadranel, Tommaso De Pas, Frank Dunphy, Katalin Udud, Myung‐Ju Ahn, Nasser H. Hanna, Ji Hyun Kim, Julien Mazières, Sang Wan Kim, Paul Baas, Erica Rappold, Suman Redhu, (unknown), Frank Wu, Pasi A. Jänne	248
10	Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer 2015 ·European Journal of Cancer ·Frances Boyle, Ian E. Smith, Joyce O’Shaughnessy, Bent Ejlertsen, Aman U. Buzdar, P. Fumoleau, William J. Gradishar, Miguel Martín, Beverly Moy, Martine Piccart, Kathleen I. Pritchard, (unknown), Mayur M. Amonkar, Yingjie Huang, Erica Rappold, Lisa S. Williams, (unknown), Tomomi Kaneko, Dianne M. Finkelstein, Paul E. Goss	8
11	Rash in Lapatinib-Treated Patients is not Associated With Human Leukocyte Antigen Polymorphisms 2015 ·Pharmacogenomics ·(unknown), Linda P. Briley, Karen S. King, Julie Byrne, Erica Rappold, Paul E. Goss, Colin F. Spraggs	1
12	MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non–small cell lung cancer (NSCLC). 2013 ·Journal of Clinical Oncology ·George R. Blumenschein, Egbert F. Smit, David Planchard, Dong‐Wan Kim, J. Cadranel, Tommaso De Pas, Frank Dunphy, Katalin Udud, Myung‐Ju Ahn, Nasser H. Hanna, Joo-Hang Kim, Julien Mazières, Sang‐We Kim, Paul Baas, Erica Rappold, Suman Redhu, Kevin M. Bellew, Michael Streit, Frank Wu, Pasi A. Jänne	18
13	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial 2012 ·The Lancet Oncology ·Paul E. Goss, Ian E. Smith, Joyce O’Shaughnessy, Bent Ejlertsen, Manfred Kaufmann, Frances Boyle, Aman U. Buzdar, P. Fumoleau, William J. Gradishar, Miguel Martín, Beverly Moy, Martine Piccart, Kathleen I. Pritchard, Deborah Lindquist, Yanin Chávarri-Guerra, Gursel Aktan, Erica Rappold, Lisa S. Williams, Dianne M. Finkelstein	100
14	HLA-DRB107:01-DQA102:01 and UGT1A128* allele carriage in hepatic serious adverse event cases identified during lapatinib clinical trials. 2011 ·Journal of Clinical Oncology ·Colin F. Spraggs, (unknown), Linda P. Briley, Charles Cox, Erica Rappold, Gursel Aktan, (unknown), Vincent Mooser, Lon R. Cardon	1
15	0154 TEACH: Phase III study of lapatinib after completion of adjuvant chemotherapy in trastuzumab-naive women with HER2-positive breast cancer 2009 ·The Breast ·Beverly Moy, J. Maltzman, Erica Rappold, (unknown), (unknown), Paul E. Goss	0
16	Hepatobiliary abnormalities in patients with metastatic cancer treated with lapatinib 2009 ·Journal of Clinical Oncology ·(unknown), Erica Rappold, L. Williams, Tracy Kelly, (unknown), J. Maltzman, Paul E. Goss	25
17	Hyperbilirubinemia in Lapatinib Treated Patients Is Associated with Gilbert's Syndrome UGT1A1 Polymorphism. 2009 ·Cancer Research ·Colin F. Spraggs, (unknown), Linda P. Briley, Nan Bing, B. Newstat, Erica Rappold, Vincent Mooser, Lon R. Cardon, S. Stein	5
18	Cardiac Safety of Lapatinib: Pooled Analysis of 3689 Patients Enrolled in Clinical Trials 2008 ·Mayo Clinic Proceedings ·Edith A. Perez, María Koehler, Julie Byrne, A. Preston, Erica Rappold, Michael S. Ewer	238
19	Cardiac safety in patients (pts) with metastatic breast cancer (MBC) treated with lapatinib (L) and trastuzumab (TRA) 2007 ·Journal of Clinical Oncology ·A. M. Storniolo, María Koehler, A. Preston, Erica Rappold, Julie Byrne, Michael S. Ewer	10
20	Gemcitabine plus paclitaxel (GT) versus paclitaxel (T) as first-line treatment for anthracycline pre-treated metastatic breast cancer (MBC): Quality of life (QoL) and pain palliation results from the global phase III study 2004 ·Journal of Clinical Oncology ·Carol M. Moinpour, (unknown), Gary Donaldson, Astra M. Liepa, Allen S. Melemed, J. O’Shaughnessy, Erica Rappold, Kathy S. Albain	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact